Drug binding to human alpha-1-acid glycoprotein in health and disease
about
TSH and Thyrotropic Agonists: Key Actors in Thyroid HomeostasispH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid)Analysis of the five glycosylation sites of human alpha 1-acid glycoproteinThe lipocalin protein family: structure and functionPharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein bindingSynthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albuminEffect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitroDiscovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female Reproductive SystemsStructural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S formsCausal Pathways from Enteropathogens to Environmental Enteropathy: Findings from the MAL-ED Birth Cohort StudyInfluence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trialAn Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia.Association of the Composite Inflammatory Biomarker GlycA, with Exercise-Induced Changes in Body Habitus in Men and Women with PrediabetesPharmacokinetics of clindamycin in pregnant women in the peripartum period.Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.Multitargeting by curcumin as revealed by molecular interaction studiesEvidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoproteinPharmacokinetics of metoclopramide in patients with liver cirrhosis.Effect of Plasmodium falciparum malaria infection on the plasma concentration of alpha 1-acid glycoprotein and the binding of quinine in Malawian childrenThe effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein.Comparison of methods for the purification of alpha-1 acid glycoprotein from human plasmaSerum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor ImatinibFLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumoniaHuman serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.Characterization of drug interactions with serum proteins by using high-performance affinity chromatography.Methadone adverse reaction presenting with large increase in plasma methadone binding: a case series.The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjectsQuinine pharmacokinetics in chronic haemodialysis patients.In vivo clearance of alpha-1 acid glycoprotein is influenced by the extent of its N-linked glycosylation and by its interaction with the vessel wall.Fucosylated Glycans in α1-Acid Glycoprotein for Monitoring Treatment Outcomes and Prognosis of Cancer Patients.Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoproteinChanges in levels of serum glycoproteins in major depressive disorders.Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar.Drug-binding energetics of human α-1-acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations.Molecular Characterization of Lipopolysaccharide Binding to Human α-1-Acid GlycoproteinDipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.Development of a novel system for mass spectrometric analysis of cancer-associated fucosylation in plasma α1-acid glycoproteinPrediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours
P2860
Q21296659-B16C6240-7E74-438E-B3C9-C258E3F6CB8AQ24527329-14D8BF25-306F-4AC7-81C5-632F9EA864A5Q24527344-E9A41E19-A196-4656-933B-A0D635512EBFQ24529878-45C50C2D-B5B7-4431-977D-4B3245453CCFQ24602935-91B09073-B0E9-4B50-91F5-144861F6CA41Q27681441-56D5BC8F-FB5D-4C74-8EE2-C4095999DBD2Q28347042-70AC17EA-7012-4E03-99FA-F8BB4BD7CA02Q28553478-C4402999-D2E9-4CE0-99EA-ACB2F3BCC21FQ30155839-D4238784-4C7B-44E9-98A4-283C063F9584Q30352850-1378DA92-B3F7-4267-9F38-55BC6784DA3FQ33348311-F0258C80-F869-4733-9B21-3735D758BAB1Q33715077-4AB2D088-D0BB-4872-B7BE-1F7E6FA850A2Q33795043-8979A7AC-F43D-4EAE-82A9-160DC03F2323Q33826411-CF3FCBA2-002B-45B1-98F7-7A046355A1B1Q33979074-F2785BD6-EE4A-4C4D-945A-E2A2C1E057DAQ33981674-64F1507F-1258-467F-B583-911D6E2C2F40Q34042485-F30991AD-5FFA-46B6-BF83-18C64AFD0256Q34345738-FEBC746D-0872-420B-A06E-94A507B8B43AQ34358153-6B396FD7-6CD6-4AB4-8ABD-B463DB767E4BQ34358661-8E0B7C35-02E7-4B33-B29F-0900690F25BEQ34398214-60E09F41-165C-4905-85F7-B6C711F5B33AQ34700333-5AF4318F-41F8-489B-8516-ADDBE02818BAQ34705820-6BAD3EB1-661E-4FDB-8232-BEAE6B668A28Q34993145-40DFD649-9D1F-4173-B804-55953B8F5C3CQ35121071-19E591A9-463C-43B2-8329-08D0F8F8A54EQ35125088-F5483165-99BC-4C71-BD4A-3C2A79306DDCQ35215569-D8974D0C-B97C-483B-8561-C370843804B9Q35448112-1E0216C7-1DFB-4EF4-95FA-4375888E0D3CQ35804001-F7DAEAB5-8826-4715-B847-D75687C51364Q35804179-DB05CD66-995E-430E-A6BB-2652C9EC4EAAQ35876153-CD4FF5D3-A58A-4B9A-9C29-8AB6A73C4CEAQ36050468-5979F0E5-7D87-4962-B6F0-4A65FDF1C7A8Q36252997-BA6373D5-41C9-46C7-B103-DF851E56DF46Q36264808-E5CB9BF2-9AF7-49D5-A535-D6C04F182175Q36331689-8AEE1408-EEF7-436C-A1A3-B272491C7C00Q36443346-4007BB47-A5C3-4C1E-BB3F-837A590302D6Q36515930-8035AF26-B611-4B10-8791-55C3E34BCCB6Q36641384-92DCF0ED-A480-46C7-A673-DC880935BFE8Q36651283-36AA163F-D16D-436D-9CA0-BB4F82CE0433Q36729934-FA3384C0-953E-4C17-921A-487DE16E300B
P2860
Drug binding to human alpha-1-acid glycoprotein in health and disease
description
1988 nî lūn-bûn
@nan
1988 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի մարտին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Drug binding to human alpha-1-acid glycoprotein in health and disease
@ast
Drug binding to human alpha-1-acid glycoprotein in health and disease
@en
Drug binding to human alpha-1-acid glycoprotein in health and disease
@nl
type
label
Drug binding to human alpha-1-acid glycoprotein in health and disease
@ast
Drug binding to human alpha-1-acid glycoprotein in health and disease
@en
Drug binding to human alpha-1-acid glycoprotein in health and disease
@nl
prefLabel
Drug binding to human alpha-1-acid glycoprotein in health and disease
@ast
Drug binding to human alpha-1-acid glycoprotein in health and disease
@en
Drug binding to human alpha-1-acid glycoprotein in health and disease
@nl
P2093
P3181
P1476
Drug binding to human alpha-1-acid glycoprotein in health and disease
@en
P2093
J M Kremer
L H Janssen
P3181
P407
P577
1988-03-01T00:00:00Z